Obesity Drug Warnings & FDA Approvals: What You Need to Know
- Food and Drug Governance asked manufacturers to remove warnings about a potential risk of suicidal thoughts from popular GLP-1 weight loss medications on January 13, 2026.This includes Novo...
- The request, as reported by Reuters, also extends to Novo Nordisk's Saxenda.
- These warnings were originally included as part of the drugs' initial approval, based on reports of similar events observed with older weight loss medications.
FDA Requests Removal of Suicide Risk Warnings for Weight Loss Drugs
The U.S. Food and Drug Governance asked manufacturers to remove warnings about a potential risk of suicidal thoughts from popular GLP-1 weight loss medications on January 13, 2026.This includes Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The request, as reported by Reuters, also extends to Novo Nordisk’s Saxenda. The FDA’s decision follows a review that found no evidence linking GLP-1 receptor agonists to an increased risk of suicidal thoughts or behavior.
These warnings were originally included as part of the drugs’ initial approval, based on reports of similar events observed with older weight loss medications. removing the warnings could alleviate a significant safety concern for this rapidly expanding class of drugs.
Researchers are currently testing or utilizing GLP-1 medications for conditions beyond weight loss, including:
- Cardiovascular issues
- Fatty liver disease
- Sleep apnea